ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed on 13 October 2026 that it bought back 134,400 H shares on the Hong Kong Stock Exchange, spending an aggregate HK$0.40 million. The shares were repurchased within a price range of HK$2.92 to HK$3.10, translating into an average buy-back price of approximately HK$3.01 per share.

Following the transaction, issued shares (excluding treasury shares) fell by 0.03% from 418.13 million to 418.00 million. Treasury shares rose to 2.48 million, while the company’s total issued share count remained unchanged at 420.48 million.

The repurchase forms part of a mandate approved on 28 May 2026 that allows IMMUNEONCO-B to buy back up to 43.15 million shares. Cumulative purchases under this mandate now stand at 2.48 million shares, equivalent to 0.57% of the issued share base on the mandate date, leaving approximately 40.67 million shares—about 94% of the authorisation—still available for future repurchases.

In line with Hong Kong listing regulations, the company is subject to a moratorium on issuing new shares or selling treasury shares until 12 November 2026.